146 related articles for article (PubMed ID: 38581349)
1. Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort.
d'Arminio Monforte A; Tavelli A; Di Biagio A; Sarmati L; Marchetti GC; Bai F; Cingolani A; Quiros Roldan E; Mussini C; Lichtner M; Vergori A; Piconi S; Orofino G; Fusco FM; Bandera A; Nozza S; Castagna A; Antinori A;
J Antimicrob Chemother; 2024 Jun; 79(6):1279-1288. PubMed ID: 38581349
[TBL] [Abstract][Full Text] [Related]
2. Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials.
Orkin C; Ajana F; Kityo C; Koenig E; Natukunda E; Gandhi-Patel B; Wang H; Liu Y; Wei X; White K; Makadzange T; Pikora C; McNicholl I; Collins SE; Brainard D; Chuck SK
J Acquir Immune Defic Syndr; 2021 Dec; 88(4):393-398. PubMed ID: 34506342
[TBL] [Abstract][Full Text] [Related]
3. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Molina JM; Ward D; Brar I; Mills A; Stellbrink HJ; López-Cortés L; Ruane P; Podzamczer D; Brinson C; Custodio J; Liu H; Andreatta K; Martin H; Cheng A; Quirk E
Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489
[TBL] [Abstract][Full Text] [Related]
4. Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial.
Mills AM; Rizzardini G; Ramgopal MN; Osiyemi OO; Bogner JR; Hagins DP; Paredes R; Reynes J; Rockstroh JK; Carr A; Su FH; Klopfer SO; Eves K; Plank RM; Correll T; Fox MC
Lancet HIV; 2024 Jun; 11(6):e357-e368. PubMed ID: 38734016
[TBL] [Abstract][Full Text] [Related]
5. Safety and adherence of bictegravir/emtricitabine/tenofovir alafenamide for HIV post-exposure prophylaxis among adults in Guiyang China: a prospective cohort study.
Gan L; Xie X; Fu Y; Yang X; Ma S; Kong L; Song C; Song Y; Ren T; Long H
BMC Infect Dis; 2024 Jun; 24(1):565. PubMed ID: 38844855
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm study.
Rodriguez CA; Natukunda E; Strehlau R; Venter EL; Rungmaitree S; Cunningham CK; Lalloo U; Kosalaraksa P; HellstrÖm E; Liberty A; McGrath EJ; Kaur M; Leisegang R; Hindman JT; Vieira VA; Kersey K; Cotton MF; Rakhmanina N; Gaur AH
Lancet HIV; 2024 May; 11(5):e300-e308. PubMed ID: 38621393
[TBL] [Abstract][Full Text] [Related]
7. Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy.
Orkin C; Antinori A; Rockstroh JK; Moreno-Guillén S; Martorell CT; Molina JM; Lazzarin A; Maggiolo F; Yazdanpanah Y; Andreatta K; Huang H; Hindman JT; Martin H; Pozniak A
AIDS; 2024 Jun; 38(7):983-991. PubMed ID: 38349226
[TBL] [Abstract][Full Text] [Related]
8. Bictegravir/emtricitabine/tenofovir alafenamide as first-line treatment in naïve HIV patients in a rapid-initiation model of care: BIC-NOW clinical trial.
Hidalgo-Tenorio C; Sequera S; Vivancos MJ; Vinuesa D; Collado A; Santos IL; Sorni P; Cabello-Clotet N; Montero M; Font CR; Terron A; Galindo MJ; Martinez O; Ryan P; Omar-Mohamed M; Albendín-Iglesias H; Javier R; Ruz MÁL; Romero A; Garcia-Vallecillos C
Int J Antimicrob Agents; 2024 Jun; 63(6):107164. PubMed ID: 38574873
[TBL] [Abstract][Full Text] [Related]
9. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study.
Hagins D; Kumar P; Saag M; Wurapa AK; Brar I; Berger D; Osiyemi O; Hileman CO; Ramgopal MN; McDonald C; Blair C; Andreatta K; Collins SE; Brainard DM; Martin H;
J Acquir Immune Defic Syndr; 2021 Sep; 88(1):86-95. PubMed ID: 34397746
[TBL] [Abstract][Full Text] [Related]
10. Integrase strand transfer inhibitor resistance mediated by R263K plus E157Q in a patient with HIV infection treated with bictegravir/tenofovir alafenamide/emtricitabine: case report and review of the literature.
Buzon-Martin L; Navarro-San Francisco C; Fernandez-Regueras M; Sanchez-Gomez L
J Antimicrob Chemother; 2024 May; 79(5):1153-1156. PubMed ID: 38558010
[TBL] [Abstract][Full Text] [Related]
11. Short-term neuropsychiatric tolerability of bictegravir combined with emtricitabine/tenofovir alafenamide in clinical practice.
Hoffmann C; Schewe K; Fenske S; Buhk T; Sabranski M; Adam A; Hansen S; Stellbrink HJ
Antivir Ther; 2020; 25(2):83-90. PubMed ID: 32235038
[TBL] [Abstract][Full Text] [Related]
12. Rapid ART initiation with bictegravir/emtricitabine/tenofovir alafenamide in individuals presenting with advanced HIV disease (Rainbow study).
Camici M; Gagliardini R; Lanini S; Del Duca G; Mondi A; Ottou S; Plazzi MM; De Zottis F; Pinnetti C; Vergori A; Grilli E; Mastrorosa I; Mazzotta V; Paulicelli J; Bellagamba R; Cimini E; Tartaglia E; Notari S; Tempestilli M; Cicalini S; Amendola A; Abbate I; Forbici F; Fabeni L; Girardi E; Vaia F; Maggi F; Antinori A
Int J Antimicrob Agents; 2024 Jan; 63(1):107049. PubMed ID: 38056572
[TBL] [Abstract][Full Text] [Related]
13. Bictegravir/emtricitabine/tenofovir alafenamide in paediatrics: Real-life experience from a French cohort (2019-2023).
Frange P; Veber F; Burgard M; Blanche S; Avettand-Fenoel V
HIV Med; 2024 Feb; 25(2):299-305. PubMed ID: 37807595
[TBL] [Abstract][Full Text] [Related]
14. Tolerability of bictegravir/tenofovir alafenamide/emtricitabine versus dolutegravir/lamivudine as maintenance therapy in a real-life setting.
Rocabert A; Borjabad B; Berrocal L; Blanch J; Inciarte A; Chivite I; Gonzalez-Cordon A; Torres B; Ambrosioni J; Martinez-Rebollar M; Laguno M; De La Mora L; Foncillas A; Sempere A; Rodriguez A; Solbes E; Llobet R; Miro JM; Mallolas J; Blanco JL; De Lazzari E; Martinez E
J Antimicrob Chemother; 2023 Dec; 78(12):2961-2967. PubMed ID: 37875023
[TBL] [Abstract][Full Text] [Related]
15. Comparing the efficacy and safety of a first-line regimen with emtricitabine/tenofovir alafenamide fumarate plus either bictegravir or dolutegravir: Results from clinical practice.
Ciccullo A; Baldin G; Borghi V; Oreni L; Lagi F; Fusco P; Giacomelli A; Torti C; Sterrantino G; Mussini C; Antinori S; Di Giambenedetto S
Int J Antimicrob Agents; 2024 Jan; 63(1):107040. PubMed ID: 37981074
[TBL] [Abstract][Full Text] [Related]
16. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.
Orkin C; DeJesus E; Sax PE; Arribas JR; Gupta SK; Martorell C; Stephens JL; Stellbrink HJ; Wohl D; Maggiolo F; Thompson MA; Podzamczer D; Hagins D; Flamm JA; Brinson C; Clarke A; Huang H; Acosta R; Brainard DM; Collins SE; Martin H; ;
Lancet HIV; 2020 Jun; 7(6):e389-e400. PubMed ID: 32504574
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide fumarate for adult patients with human immunodeficiency virus-1 in China: a retrospective real-world cohort study.
Gan L; Xie X; Fu Y; Song Y; Song C; Ren T; Long H
Expert Rev Anti Infect Ther; 2024 Apr; 22(4):211-217. PubMed ID: 38058002
[TBL] [Abstract][Full Text] [Related]
18. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Gallant J; Lazzarin A; Mills A; Orkin C; Podzamczer D; Tebas P; Girard PM; Brar I; Daar ES; Wohl D; Rockstroh J; Wei X; Custodio J; White K; Martin H; Cheng A; Quirk E
Lancet; 2017 Nov; 390(10107):2063-2072. PubMed ID: 28867497
[TBL] [Abstract][Full Text] [Related]
19. Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States.
Emond B; Rossi C; Côté-Sergent A; Bookhart B; Anderson D; Lefebvre P; Lafeuille MH; Donga P
Curr Med Res Opin; 2022 Feb; 38(2):287-298. PubMed ID: 34812097
[TBL] [Abstract][Full Text] [Related]
20. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance.
Acosta RK; Willkom M; Andreatta K; Liu H; Martin R; Parvangada A; Martin H; Collins S; White KL
J Acquir Immune Defic Syndr; 2020 Nov; 85(3):363-371. PubMed ID: 32701823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]